ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
61 223,41
0,70%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. IGC Pharma Inc (IGC)

  7. IGC Pharma Inc (IGC) Actualités

IGC

IGC Pharma (IGC)

IGC Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:AMEX:IGC
DateHeureSourceTitreSymboleSociété
16/04/202413h00Business WireIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoAMEX:IGCIGC Pharma Inc
09/04/202415h00Business WireIGC Pharma Adds Advisor in Artificial IntelligenceAMEX:IGCIGC Pharma Inc
26/03/202420h00Business WireIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockAMEX:IGCIGC Pharma Inc
20/03/202416h00Business WireIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationAMEX:IGCIGC Pharma Inc
20/03/202412h00Business WireIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024AMEX:IGCIGC Pharma Inc
12/03/202420h00Business WireIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineAMEX:IGCIGC Pharma Inc
28/02/202419h00Business WirePromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
23/02/202418h01Business WireIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price TargetAMEX:IGCIGC Pharma Inc
17/02/202401h05Business WireIGC Pharma Reports Third Quarter Fiscal 2024 ResultsAMEX:IGCIGC Pharma Inc
14/02/202422h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
01/02/202415h20Business WireIGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
31/01/202422h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:IGCIGC Pharma Inc
23/01/202415h20Business WireIGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’sAMEX:IGCIGC Pharma Inc
17/01/202415h20Business WireIGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s TrialAMEX:IGCIGC Pharma Inc
09/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:IGCIGC Pharma Inc
29/12/202322h54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933AMEX:IGCIGC Pharma Inc
19/12/202315h20Business WirePatent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’sAMEX:IGCIGC Pharma Inc
13/12/202315h30Business WireIGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024AMEX:IGCIGC Pharma Inc
06/12/202314h30Business WireIGC Pharma Announces Collaboration to Integrate AI into Clinical TrialsAMEX:IGCIGC Pharma Inc
21/11/202314h30Business WireIGC Pharma Announces Master Agreement with Leading South American University to Advance AI InitiativesAMEX:IGCIGC Pharma Inc
13/11/202314h00Business WireIGC Pharma Reports Second Quarter Fiscal 2024 ResultsAMEX:IGCIGC Pharma Inc
27/10/202323h21Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
19/10/202321h30Business WireIGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief TherapyAMEX:IGCIGC Pharma Inc
21/08/202320h30Business WireIGC Announces Results of its 2023 Annual Stockholders MeetingAMEX:IGCIGC Pharma Inc
14/08/202314h30Business WireIGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical TrialsAMEX:IGCIGC Pharma Inc
02/08/202314h30Business WireIGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto RicoAMEX:IGCIGC Pharma Inc
26/07/202323h26Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:IGCIGC Pharma Inc
18/07/202311h22Business WireIGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International ConferenceAMEX:IGCIGC Pharma Inc
12/07/202314h44Business WireIGC Reports Financial Results for Fiscal Year Ended March 31, 2023AMEX:IGCIGC Pharma Inc
07/07/202322h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:IGCIGC Pharma Inc
 Showing the most relevant articles for your search:AMEX:IGC

Dernières Valeurs Consultées

EU
ORA
Orange
NYSE
JPM
JP Morgan Chase
EU
AI
Air Liquide
NYSE
DIS
Walt Disney
COIN
ETHUSD
Ethereum
EU
CAP
Capgemini
EU
VK
Vallourec
NASDAQ
GOOGL
Alphabet
NYSE
KO
Coca Cola
NYSE
NKE
Nike
EU
DG
Vinci
NASDAQ
AMZN
Amazon.com
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés